Results 11 to 20 of about 3,160 (160)

TR-FRET between engineered nanobodies reveals the existence of endogenous CXCR4 oligomers [PDF]

open access: yesCommunications Biology
Chemokine receptors CXCR4 and ACKR3 are involved in multiple physiological and pathological processes. In overexpression systems, CXCR4 and ACKR3 form oligomers that are important for chemokine recognition and signaling.
Joyce Heuninck   +17 more
doaj   +2 more sources

ACKR3 Regulation of Neuronal Migration Requires ACKR3 Phosphorylation, but Not β-Arrestin

open access: yesCell Reports, 2019
Summary: Phosphorylation of heptahelical receptors is thought to regulate G protein signaling, receptor endocytosis, and non-canonical signaling via recruitment of β-arrestins.
Dagmar Schuetz   +2 more
exaly   +3 more sources

Heterogeneous expression of the atypical chemokine receptor ACKR3 in glioblastoma patient-derived tissue samples and cell cultures [PDF]

open access: yesScientific Reports
Glioblastoma (GBM) is the most aggressive glial tumor of the adult brain, associated with invariably fatal outcome, and a deeper understanding of the underlying malignant mechanisms is necessary to address the current therapeutic failure.
Damla Isci   +9 more
doaj   +2 more sources

Atlas of the anatomical localization of atypical chemokine receptors in healthy mice. [PDF]

open access: yesPLoS Biology, 2023
Atypical chemokine receptors (ACKRs) scavenge chemokines and can contribute to gradient formation by binding, internalizing, and delivering chemokines for lysosomal degradation.
Serena Melgrati   +8 more
doaj   +3 more sources

Targeting the CXCL12/CXCR4 pathway by an optimized derivative or EPI-X4 preserves chondrocyte function and offers a novel therapeutic approach in rheumatic diseases [PDF]

open access: yesArthritis Research & Therapy
Background The C-X-C motif chemokine 12 (CXCL12) and its receptor CXCR4 are pivotal in tissue regeneration and inflammation, yet their role in osteoarthritis (OA) remains ambiguous.
Leonie Ruths   +7 more
doaj   +2 more sources

CXCR7 is highly expressed in acute lymphoblastic leukemia and potentiates CXCR4 response to CXCL12. [PDF]

open access: yesPLoS ONE, 2014
Recently, a novel CXCL12-binding receptor, has been identified. This CXCL12-binding receptor commonly known as CXCR7 (CXC chemokine receptor 7), has lately, based on a novel nomenclature, has received the name ACKR3 (atypical chemokine receptor 3).
Rita de Cássia Carvalho Melo   +7 more
doaj   +4 more sources

GPR182 is a broadly scavenging atypical chemokine receptor influencing T-independent immunity [PDF]

open access: yesFrontiers in Immunology, 2023
Immune responses highly depend on the effective trafficking of immune cells into and within secondary lymphoid organs (SLOs). Atypical chemokine receptors (ACKRs) scavenge chemokines to eliminate them from the extracellular space, thereby generating ...
Serena Melgrati   +16 more
doaj   +3 more sources

The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides

open access: yesNature Communications, 2020
Opioids modulate pain, anxiety and stress by activating four subtypes of opioid receptors. The authors show that atypical chemokine receptor 3 (ACKR3) is a scavenger for various endogenous opioid peptides regulating their availability without activating ...
Max Meyrath   +2 more
exaly   +2 more sources

Emerging roles of atypical chemokine receptor 3 (ACKR3) in normal development and physiology [PDF]

open access: yesCytokine, 2018
The discovery that atypical chemokine receptors (ACKRs) can initiate alternative signaling pathways rather than classical G-protein coupled receptor (GPCR) signaling has changed the paradigm of chemokine receptors and their roles in modulating ...
Caron, K.M., Mackie, D.I., Quinn, K.E.
exaly   +3 more sources

Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies [PDF]

open access: yesNature Communications
G protein-coupled receptors (GPCRs) are pivotal therapeutic targets, but their complex structure poses challenges for effective drug design. Nanobodies, or single-domain antibodies, have emerged as a promising therapeutic strategy to target GPCRs ...
Roman R. Schlimgen   +5 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy